tirzepatide and osa Diabetes & Weight Loss Drug Now Approved for (Obstructive Sleep Apnea) Tirzepatide for OSA

doi:10.4161/epi.25798

Each program targets a specific biological outcome

Strength of recommendation: 2C Rationale: Low-dose aspirin (75100mg/day) should be prescribed for secondary prevention of atherosclerotic cardiovascular disease among patients with diabetes and CKD and atherosclerotic cardiovascular disease, according to all guidelines and the available evidence.104108 The recent post hoc analysis of the ADAPTABLE trial among the subset of patients with diabetes showed that there were no differences in terms of efficacy and safety of low dose (81mg/day vs

If response and tolerability look good, switch to prepay for the savings